• Explore /
  • Poster
  • / Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- or second-line immunotherapies (IO) in the United States (US).

Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- or second-line immunotherapies (IO) in the United States (US).

Abstract Poster

Authors

null

Marley Boyd

The US Oncology Network, McKesson Specialty Health, Houston, TX

Marley Boyd , Srinivas Annavarapu , Gurjyot K. Doshi , Kentaro Imai , Eric Sbar , James Luke Godwin , Haojie Li , Guru Sonpavde

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 457)

Abstract #

457

Poster Bd #

G2

Abstract Disclosures

Similar Posters

First Author: Guenter Niegisch

First Author: Julie M. Shabto

First Author: Julie M. Shabto

First Author: Julie M. Shabto